Showing results (81-90 of 809) with videos related to
Sort By:
Pageof 81
Clinical Lipidology|November 7, 2014
Monogenic causes of elevated HDL cholesterol and implications for development of new therapeuticsDaniel B Larach, Marina Cuchel, Daniel J RaderCirculation Research|September 24, 2005
Apolipoprotein E suppresses the type I inflammatory response in vivoKamilah Ali, Melissa Middleton, Ellen Puré, et al.Journal of the American College of Cardiology|June 7, 2008
Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approachesEmil M deGoma, Rolando L deGoma, Daniel J RaderScience Translational Medicine|July 24, 2010
Could exercise metabolomics pave the way for gymnomimetics?Megan F Burke, Richard L Dunbar, Daniel J RaderCirculation Research|June 7, 2014
Lipoproteins as biomarkers and therapeutic targets in the setting of acute coronary syndromeRobert S Rosenson, H Bryan Brewer, Daniel J RaderEuropean Heart Journal. Cardiovascular Pharmacotherapy|September 22, 2022
RNA-targeted therapeutics in cardiovascular disease: the time is nowKonstantin A Krychtiuk, Daniel J Rader, Christopher B GrangerBiochemical Society Transactions|October 31, 2015
Tribbles-1: a novel regulator of hepatic lipid metabolism in humansRobert C Bauer, Batuhan O Yenilmez, Daniel J RaderEndocrinology|May 22, 2002
Perspective: cardiovascular disease in the postgenomic era--lessons learned and challenges aheadJonathan A Epstein, Daniel J Rader, Michael S ParmacekThe Journal of Biological Chemistry|June 29, 2010
Angiopoietin-like protein 3 inhibits lipoprotein lipase activity through enhancing its cleavage by proprotein convertasesJun Liu, Huq Afroza, Daniel J Rader, et al.Clinical Lipidology|April 17, 2012
Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategiesSadik H Kassim, James M Wilson, Daniel J RaderPageof 81